Advanced search
Publication Cover
Cancer Investigation Volume 26, 2008 - Issue 1
Submit an article Journal homepage
101
Views
16
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEClinical Translational Therapeutics

Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study

Andrew H. Ko University of California at San Francisco Comprehensive Cancer Center, San Francisco, California, USA
,
Elizabeth Dito University of California at San Francisco Comprehensive Cancer Center, San Francisco, California, USA
,
Brian Schillinger University of California at San Francisco Comprehensive Cancer Center, San Francisco, California, USA
,
Alan P. Venook University of California at San Francisco Comprehensive Cancer Center, San Francisco, California, USA
,
Emily K. Bergsland University of California at San Francisco Comprehensive Cancer Center, San Francisco, California, USA
&
Margaret A. Tempero University of California at San Francisco Comprehensive Cancer Center, San Francisco, California, USA
Pages 47-52 | Published online: 11 Jun 2009

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jie Hua, Si Shi, Dingkong Liang, Chen Liang, Qingcai Meng, Bo Zhang, Quanxing Ni, Jin Xu & Xianjun Yu. (2018) Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?. OncoTargets and Therapy 11, pages 4591-4608.
Read now
Katharina Elisabeth Tschoep-Lechner, Valeria Milani, Frank Berger, Nelli Dieterle, Sultan Abdel-Rahman, Christoph Salat & Rolf-Dieter Issels. (2013) Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. International Journal of Hyperthermia 29:1, pages 8-16.
Read now

Articles from other publishers (14)

M. Bupathi, D. H. Ahn, C. Wu, K. K. Ciombor, J. A. Stephens, J. Reardon, D. A. Goldstein & T. Bekaii-Saab. (2016) Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Medical Oncology 33:4.
Crossref
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, Andrew Dean, Yan-Shen Shan, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, Jean F Blanc, Richard A Hubner, Chang-Fang Chiu, Gilberto Schwartsmann, Jens T Siveke, Fadi Braiteh, Victor Moyo, Bruce Belanger, Navreet Dhindsa, Eliel Bayever, Daniel D Von Hoff, Li-Tzong Chen, Clarence Adoo, Thomas Anderson, Jamil Asselah, Alan Azambuja, Carolyn Bampton, Carlos Henrique Barrios, Tanios Bekaii-Saab, Melichar Bohuslav, David Chang, Jen-Shi Chen, Yeu-Chin Chen, Hye Jin Choi, Ik Joo Chung, Vincent Chung, Tibor Csoszi, Antonio Cubillo, Linda DeMarco, Maike de Wit, Tomislav Dragovich, William Edenfield, Luis Enrique Fein, Fábio Franke, Martin Fuchs, Vega Gonzales-Cruz, Alberto Gozza, Rivera Herrero Fernando, Rosario Iaffaioli, Jitka Jakesova, Zsuzsanna Kahan, Misagh Karimi, Jun Suk Kim, Ernesto Korbenfeld, Istvan Lang, Fa-Chyi Lee, Kuan-Der Lee, Lara Lipton, Wen Wee Ma, Laszlo Mangel, Raul Mena, Daniel Palmer, Shubham Pant, Joon Oh Park, Paolo Piacentini, Uwe Pelzer, Javier Gallego Plazas, Cooray Prasad, Kun-Ming Rau, Jean-Luc Raoul, Donald Richards, Paul Ross, Luis Schlittler, Martin Smakal, Vladimira Stahalova, Cora Sternberg, Thomas Seufferlein, Niall Tebbutt, Jeferson Jose Vinholes, Raymond Wadlow, Milkos Wenczl & Mark Wong. (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. The Lancet 387:10018, pages 545-557.
Crossref
Adnan M. Nagrial, Venessa T. Chin, Katrin M. Sjoquist, Marina Pajic, Lisa G. Horvath, Andrew V. Biankin & Desmond Yip. (2015) Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology/Hematology 96:3, pages 483-497.
Crossref
E. Gabriela Chiorean & Daniel D. Von Hoff. (2014) Taxanes. Anti-Cancer Drugs 25:5, pages 584-592.
Crossref
A H Ko, M A Tempero, Y-S Shan, W-C Su, Y-L Lin, E Dito, A Ong, Y-W Wang, C G Yeh & L-T Chen. (2013) A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. British Journal of Cancer 109:4, pages 920-925.
Crossref
Russel Wynn & Sebastian Krastel. (2013) An unprecedented Western Palearctic concentration of Wilson’s Storm-petrels Oceanites oceanicus at an oceanic upwelling front offshore Mauritania. Seabird Journal:25, pages 47-53.
Crossref
Hassan K. Dakik, Daniel J. Moskovic, Peter J. Carlson, Eric P. Tamm, Wei Qiao, Robert A. Wolff, James L. Abbruzzese & David R. Fogelman. (2011) The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology 69:2, pages 425-430.
Crossref
Uwe Pelzer, Ingo Schwaner, Jens Stieler, Mathias Adler, J?rg Seraphin, Bernd D?rken, Hanno Riess & Helmut Oettle. (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group. European Journal of Cancer 47:11, pages 1676-1681.
Crossref
Jeong Youp Park. (2011) Second Line Chemotherapy for Pancreatic Cancer. The Korean Journal of Gastroenterology 57:4, pages 207.
Crossref
Andrew H. Ko, Alan P. Venook, Emily K. Bergsland, R. Kate Kelley, W. Michael Korn, Elizabeth Dito, Brian Schillinger, Janet Scott, Jimmy Hwang & Margaret A. Tempero. (2010) A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology 66:6, pages 1051-1057.
Crossref
A. Todaka, A. Fukutomi, N. Boku, Y. Onozawa, S. Hironaka, H. Yasui, K. Yamazaki, K. Taku, N. Machida, T. Sakamoto & H. Tomita. (2010) S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure. Japanese Journal of Clinical Oncology 40:6, pages 567-572.
Crossref
Sharmila P. Mehta. (2010) Palliative Chemotherapy for Pancreatic Malignancies. Surgical Clinics of North America 90:2, pages 365-375.
Crossref
Ben LawrenceMichael Findlay. (2010) Systemic therapy for metastatic pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology 2:2, pages 85-106.
Crossref
. (2009) Current World Literature. Current Opinion in Supportive & Palliative Care 3:1, pages 79-89.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.